联合检测前列腺癌组织Notch1、FLNA表达的临床意义  

Clinical significance of combined detection of Notch1 and FLNA expression in prostate cancer tissue

作　　者：马阔 李泽宇 刘沛[1] 韩广业[1] MA Kuo;LI Zeyu;LIU Pei;HAN Guangye(Department of Urology,the First Affiliated Hospital of Xinxiang Medical College,Xinxiang 453100,China)

机构地区：[1]新乡医学院第一附属医院泌尿外科,河南新乡453100

出　　处：《东南大学学报(医学版)》2025年第1期30-37,共8页Journal of Southeast University(Medical Science Edition)

基　　金：河南省医学科技攻关计划项目(LHGJ20220607)。

摘　　要：目的:分析前列腺癌组织缺刻基因1(Notch1)和细丝蛋白A(FLNA)的表达水平与临床病理特征的关系及其对预后的预测价值。方法:收集2018年7月到2020年12月在本院接受根治性手术的112例前列腺癌患者为研究对象,根据预后情况分为预后良好组(79例)和预后不良组(33例)。采用免疫组化法测定前列腺癌和癌旁组织中Notch1蛋白和FLNA的表达情况;实时荧光定量PCR(qPCR)法检测组织中Notch1 mRNA和FLNA mRNA表达水平;Kaplan-Meier生存曲线分析Notch1 mRNA、FLNA mRNA表达水平与患者预后生存率关系;绘制受试者工作特征(ROC)曲线分析前列腺癌组织中Notch1 mRNA和FLNA mRNA表达对患者预后的预测效能。结果:前列腺癌组织Notch1蛋白阳性率为81.25%,高于癌旁组织的21.43%(P<0.05);FLNA阳性率为20.54%,低于癌旁组织的77.68%(P<0.05)。前列腺癌组织Notch1 mRNA、F LNA mRNA表达水平与患者年龄、Gleason评分、微血管侵犯、包膜侵犯、精囊侵犯、神经周围侵犯、手术切缘阳性、TNM分期和前列腺特异性抗原(PSA)有关(P<0.05)。与预后良好组(Notch1 mRNA=1.45±0.29,FLNA mRNA=0.87±0.17)相比,预后不良组患者前列腺癌组织中Notch1 mRNA(2.01±0.44)表达水平升高(P<0.05),FLNA mRNA(0.68±0.13)表达水平下降(P<0.05)。前列腺癌患者3年生存率为70.54%(79/112),Notch1 mRNA高表达组患者3年生存率(55.17%)低于低表达组(87.04%)(Log-rankχ^(2)=14.492,P<0.001),FLNA mRNA高表达组3年生存率(82.46%)高于低表达组(58.18%)(Log-rankχ^(2)=8.532,P=0.003)。ROC曲线结果显示前列腺癌组织Notch1 mRNA和FLNA mRNA联合预测预后的AUC为0.874,显著大于Notch1 mRNA(Z=2.035,P=0.042)和FLNA mRNA(Z=2.270,P=0.023)单独预测。结论:前列腺癌组织Notch1蛋白阳性率高于癌旁组织,FLNA阳性率低于癌旁组织,两者与患者临床特征和预后具有相关性,两者mRNA联合检测对患者预后预测效能较高。Objective:To analyze the expression levels of Notch1 gene and Filamin A(FLNA)protein in prostate cancer tissue and their relationship with clinical pathological features and predictive value for prognosis.Methods:A total of 112 prostate cancer patients who underwent radical surgery from July 2018 to December 2020 were collected as research subjects and divided into a good prognosis group of 79 cases and a poor prognosis group of 33 cases according to the prognosis.Immunohistochemistry was used to determine the expression of Notch1 protein and FLNA in prostate cancer and adjacent tissues;real-time fluorescence quantitative PCR(qPCR)was used to detect the expression levels of Notch1 mRNA and FLNA mRNA in tissues;Kaplan-Meier survival curves were used to analyze the relationship between the expression levels of Notch1 mRNA and FLNA mRNA and the patients'prognosis survival rate;the receiver operating characteristic(ROC)curve was plotted to analyze the predictive efficacy of Notch1 mRNA and FLNA mRNA expression in prostate cancer tissue for patients'prognosis.Results:The positive rate of Notch1 protein in prostate cancer tissues(81.25%)was higher than that in adjacent tissues(21.43%),and the positive rate of FLNA(20.54%)was lower than that in adjacent tissues(77.68%)(P<0.05).The expression levels of Notch1 mRNA and FLNA mRNA in prostate cancer tissues were related to age,Gleason score,microvascular invasion,capsule invasion,seminal vesicle invasion,perineural invasion,positive surgical margin,TNM stage and prostate-specific antigen(PSA)(P<0.05).Compared with the good prognosis group(Notch1 mRNA=1.45±0.29,FLNA mRNA=0.87±0.17),the expression level of Notch1 mRNA(2.01±0.44)in prostate cancer tissues of the poor prognosis group was increased(P<0.05),FLNA mRNA(0.68±0.13)decreased(P<0.05);the 3-year survival rate of prostate cancer patients was 70.54%(79/112),and the 3-year survival rate of patients with high expression of Notch1 mRNA(55.17%)was lower than that of the low expression group(87.04%)(Log-rankχ^(2)=14.492,P

关 键 词：前列腺癌 缺刻基因1 细丝蛋白A 临床特征 预后 

分 类 号：R737.25[医药卫生—肿瘤]